Soft Gel Estradiol Composition for VVA Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vulvovaginal atrophy (VVA) in postmenopausal women face challenges such as compliance issues due to the form of estradiol administration, including vaginal dryness, irritation, and increased susceptibility to infections, despite estrogen treatment being effective in relieving symptoms.
Innovation Solution
A soft gel vaginal pharmaceutical composition containing solubilized estradiol with a medium chain oil as a solubilizing agent, such as caprylic/capric triglyceride, is developed to improve safety, efficacy, and patient compliance, providing a therapeutically effective dosage form that minimizes vaginal discharge and ensures effective estradiol absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaginal estradiol formulations are used, then VVA symptoms can be relieved, but compliance issues occur due to treatment form problems
Solution Approach 1:
The patent changes the physical state parameter of estradiol from solid to solubilized form in medium chain oil, creating a soft gel formulation that is easier to administer and more comfortable for patients, thereby improving compliance while maintaining treatment efficacy
Solution Approach 2:
The patent creates a composite pharmaceutical composition by combining estradiol with medium chain oil solubilizing agents, resulting in a soft gel formulation that integrates both the active ingredient and delivery vehicle into a single patient-friendly dosage form
2Reliability
If vaginal estradiol treatment is administered, then VVA symptoms are relieved, but vaginal discharge increases
Solution Approach 1:
The patent modifies the formulation parameters by using solubilized estradiol in medium chain oil rather than traditional solid or aqueous formulations, which reduces vaginal discharge as a harmful side effect while preserving the therapeutic benefits for VVA symptom relief
3Reliability
If solubilized estradiol in medium chain oil is used, then bioavailability and absorption are improved, but formulation complexity increases
Solution Approach 1:
The patent introduces medium chain oil as an intermediary solubilizing agent that facilitates the dissolution and absorption of estradiol, improving bioavailability through this intermediate medium while keeping the overall formulation process manageable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The soft gel composition achieves improved bioavailability and absorption of estradiol, reducing VVA symptoms like vaginal dryness, irritation, and pain, while minimizing systemic exposure and vaginal discharge, thus enhancing treatment compliance and efficacy.
Implementation Method 1
a soft gel vaginal pharmaceutical composition containing solubilized estradiol with a medium chain oil as a solubilizing agent
Data Source
AI summary
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).